Journal of Dermatological Treatment This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Rapid and sustained improvements in itch and quality of life with upadacitinib plus topical corticosteroids in adults and adolescents with atopic dermatitis: 52-week outcomes from the phase 3 AD Up study
Conclusions: Upadacitinib + TCS results in rapid, sustained improvements in burdensome AD symptoms and QoL.PMID:38697950 | DOI:10.1080/09546634.2024.2344589 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - May 2, 2024 Category: Dermatology Authors: Nina Magnolo Michael C Cameron Mona Shahriari Bob Geng Brian M Calimlim Henrique Teixeira Xiaofei Hu Yang Yang Yingyi Liu Shiyu Zhang Cristina Sancho Sanchez Katherine Altman Richard G Langley Source Type: research

Statement of retraction: evidence-based clinical practice guidelines for the management of psoriasis: systematic review, critical appraisal, and quality assessment with the AGREE II instrument
J Dermatolog Treat. 2024 Dec;35(1):2334685. doi: 10.1080/09546634.2024.2334685. Epub 2024 Apr 29.NO ABSTRACTPMID:38684214 | DOI:10.1080/09546634.2024.2334685 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 29, 2024 Category: Dermatology Source Type: research

Clinical course and disease burden of patients with generalized pustular psoriasis in Portugal: a multicenter retrospective cohort study
CONCLUSIONS: Our study demonstrates that GPP is a chronic, debilitating condition associated with systemic involvement, frequent flares, and hospitalizations, despite receiving multiple systemic treatments. Improved disease awareness and new treatments are needed to improve patient care and decrease the burden of the disease.PMID:38684228 | DOI:10.1080/09546634.2024.2345728 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 29, 2024 Category: Dermatology Authors: Tiago Torres Joana Antunes Ana Brasileiro Jo ão Alves Diana Bernardo Jos é Ramos Diogo Sousa Cristina Castro Ana Gusm ão Palmeiro Andr é Aparício Martins Joana Fazendeiro Matos B árbara Vieira Granja Pedro Ponte Gabriela Marques Pinto Paula Quirino Source Type: research

Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials
CONCLUSIONS: Improvement in itch and sleep interference due to itch is associated with improvement in the QoL of patients after treatment with lebrikizumab for moderate-to-severe AD.ClinicalTrials.gov registration NCT04146363 (ADvocate1) and NCT04178967 (ADvocate2).PMID:38679419 | DOI:10.1080/09546634.2024.2329240 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 28, 2024 Category: Dermatology Authors: Jennifer Soung Sonja St änder Jan Gutermuth Ignasi Pau-Charles Zach Dawson Fan Emily Yang Luna Sun Evangeline Pierce Hany Elmaraghy Linda Stein-Gold Source Type: research

Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
CONCLUSIONS: Upadacitinib was therapeutically effective and tolerable for moderate-to-severe AD through 48 weeks in real-world clinical practice.PMID:38653561 | DOI:10.1080/09546634.2024.2344591 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 23, 2024 Category: Dermatology Authors: Teppei Hagino Hidehisa Saeki Eita Fujimoto Naoko Kanda Source Type: research

Tofacitinib for managing granuloma formation after dermal filler injection: three case reports and literature review
CONCLUSION: This report emphasizes the effectiveness of JAK inhibitors in treating granulomas caused by filler injections. Recent advancements in understanding the underlying mechanisms of granulomatous reactions have paved the way for JAK inhibitors to be regarded as a promising treatment choice. However, further research is necessary to fully assess the safety and long-term effectiveness of using tofacitinib for granuloma treatment.PMID:38632962 | DOI:10.1080/09546634.2024.2338281 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Jieyi Wang Zhuoxuan Chen Lin Wu Yan Liao Bo Yu Source Type: research

Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials
J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18.ABSTRACTIn the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This post hoc integrated analysis evaluated achieving the following efficacy outcomes at weeks 24 and 52 by baseline demographics and clinical characteristics: ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70), ≥90% improvement in Psoriasis Area and Severity Index, minimal disease act...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Joseph F Merola April Armstrong Saakshi Khattri So Yeon Paek Byron Padilla Cuiyong Yue Huzefa Photowala Blair Kaplan Lars Erik Kristensen Source Type: research